Adaptive dose selection using efficacy-toxicity trade-offs: Illustrations and practical considerations

Journal of Biopharmaceutical Statistics

Volumn 16, Issue 5, 2006, Pages 623-638

  Thall, Peter F ^a   Cook, John D ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute leukemia; Adaptive design; Bayesian design; Phase I clinical trial; Phase I II clinical trial

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; CYTARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALGORITHM; ARTICLE; BAYES THEOREM; BONE MARROW TOXICITY; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER SIMULATION; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; EXPERIMENTAL THERAPY; FATALITY; HUMAN; INFECTION; LEUKOPENIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL; UNSPECIFIED SIDE EFFECT; VOMITING;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MODELS, STATISTICAL; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33751584603     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400600860394     Document Type: Article

References (11)

1. Bekele B. N., Thall, P. F. (2004). Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J. Am. Stat. Assoc. 99:26-35.
2. Bekele, B. N., Shen, Y. (2005). A Bayesian approach to jointly modeling toxicity and biomarker expression in a Phase I/II dose-finding trial. Biometrics 61:343-354.
3. Braun, T. (2002). The bivariate continual reassessment method: extending the CRM to Phase I trials of two competing outcomes. Controlled Clin. Trials 23:240-256.
4. Gooley, T. A., Martin, P. J., Fisher, L. D., Pettinger, M. (1994). Simulation as a design tool for Phase I/II clinical trials: an example from bone marrow transplantation. Controlled Clin. Trials 15:450-462.
5. Ivanova, A. (2003). A new dose-finding design for bivariate outcomes. Biometrics 59:1001-1007.
6. Murtaugh, P. A., Fisher, L. D. (1990). Bivariate binary models of efficacy and toxicity in dose-ranging trials. Commun. Stat. Part A Theory Methods 19:2003-2020.
7. O'Quigley, J., Hughes, M. D., Fenton, T. (2001). Dose-finding designs for HIV studies. Biometrics 57:1018-1029.
8. Prentice, R. L. (1988). Correlated binary regression with covariates specific to each binary observation. Biometrics 44:1033-1048.
9. Thall, P. F., Cook, J. D. (2004). Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60:684-693.
10. Thall, P. F., Sung, H.-G., Estey, E. H. (2002). Selecting therapeutic strategies based on efficacy and death in multi-course clinical trials. J. Am. Stat. Assoc. 97:29-39.
11. Zelen, M. (1969). Play the winner rule and the controlled clinical trial. J. Am. Stat. Assoc. 64:131-146.